Therapy Area

FDA extends review period for Pfizer-Myovant’s sNDA for Myfembree

The regulatory agency needs additional time for reviewing further data on bone mineral density.

Latest in Therapy Area

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive.

A weekly roundup of the latest news and analysis, sent every Friday.

The pharmaceutical industry's most comprehensive news and information delivered every month.

I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy

SUBSCRIBED